Pharma & Life Sciences — April 2, 2026

FY 2027 Hospice Wage Index Payment Rate Update and Quality Reporting Program Proposed Rule

CMS issued proposed rule CMS-1851-P to update Medicare hospice payments for FY 2027, proposing a 2.4% payment rate increase ($785M estimated impact). The rule includes new Service and Spending Variation Index (SSVI) for oversight, mandatory hospice election addendum requirements, and changes to physician designee discharge authority.

FY 2027 Inpatient Rehabilitation Facility Prospective Payment System Proposed Rule

CMS issued a proposed rule updating Medicare payment policies for Inpatient Rehabilitation Facilities for FY 2027, proposing a 2.4% payment rate increase based on a 3.2% market basket update less a 0.8% productivity adjustment. The rule includes an estimated $355 million increase in IRF payments, updates to outlier thresholds and case-mix weights, and proposes clarifying that all therapies must be initiated within 36 hours of IRF admission.

Medicare Inpatient Psychiatric Facility Payment System Updates for FY 2027

CMS issued a proposed rule to update Medicare payment policies for Inpatient Psychiatric Facilities (IPF) for FY 2027, proposing a 2.3% payment rate update representing a $50 million increase in total payments. The rule includes proposals to reform outlier payment policy, remove two measures from the IPF Quality Reporting Program, and implement a standardized IPF patient assessment instrument.

FY 2027 Skilled Nursing Facility Prospective Payment System Proposed Rule

CMS issued a proposed rule (CMS-1843-P) updating Medicare payment policies and rates for skilled nursing facilities under the SNF Prospective Payment System for FY 2027. The proposed payment update is 2.4%, based on a 3.2% market basket update offset by a 0.8% productivity adjustment. CMS also proposes changes to the SNF Quality Reporting Program and Value-Based Purchasing Program.

Hospice Scoring System for Fraud Detection and Transparency

CMS announced a proposed rule (FY 2027 Hospice Wage Index and Payment Rate Update) introducing a new Hospice Service and Spending Variation Index (SSVI) to publicly score hospice providers based on indicators of inappropriate utilization, quality of care, and compliance concerns. The scoring system aims to combat fraud in the Medicare hospice program, with enhanced oversight already resulting in over 200 enrollment revocations in Arizona, California, Nevada, and Texas, now expanding to additional states.

Medicare Advantage and Part D Contract Year 2027 Final Rule

CMS issued a final rule updating Medicare Advantage and Part D programs for Contract Year 2027. The rule modifies the Star Ratings system by removing 11 administrative measures and adding a depression screening measure, while codifying Inflation Reduction Act provisions including elimination of the coverage gap phase and reduced annual out-of-pocket thresholds. The rule impacts Medicare Advantage organizations, Part D sponsors, and approximately 66 million Medicare beneficiaries.

FY 2027 IPF Payment Rate Update

CMS published a proposed rule updating Inpatient Psychiatric Facility (IPF) payment rates for Fiscal Year 2027. The notice affects Medicare-participating IPFs and includes potential changes to payment amounts, wage indices, and facility-level adjustments. Public comments are being accepted through the specified deadline.

SNF Prospective Payment System FY2027 Quality Reporting Updates

CMS published a proposed rule updating the Skilled Nursing Facility Prospective Payment System quality reporting requirements for FY2027. The rule proposes changes to standardized patient assessment data reporting under the Minimum Data Set and modifies quality measures for the SNF Quality Reporting Program. Skilled nursing facilities participating in Medicare would be subject to these updated reporting requirements and potential payment adjustments tied to quality performance.

Hospice Wage Index FY 2027 Payment Update Proposal

CMS has published a proposed rule to update the hospice wage index and payment rates for Fiscal Year 2027. The proposal affects Medicare-certified hospice providers and includes changes to routine home care rates, continuous home care rates, and other service payment categories. Comments are being solicited on the payment methodology updates and wage index adjustments.

IRF Payment Rates and Quality Reporting Updates for FY2027

CMS published a proposed rule to update Inpatient Rehabilitation Facility (IRF) payment rates and quality reporting requirements for Fiscal Year 2027. The rule affects Medicare-certified IRFs and proposes changes to payment methodology and quality measure reporting under the IRF Quality Reporting Program.

Maincare IC Prescription Module Safety Notice

ANSM issued a safety notice (n° R2609195) informing healthcare services that Maincare Solutions has implemented a security action on its IC prescription module software. Users of the affected software have received direct correspondence from the manufacturer regarding this action.

Inogen Rove 6 oxygen concentrator safety notice

ANSM has issued safety notice R2608138 informing three French home health providers about a field safety corrective action by manufacturer Inogen Inc. regarding the Inogen Rove 6 portable oxygen concentrator. The action was conducted directly by Inogen Inc., with ANSM acting as the notification authority. Providers should consult the attached manufacturer correspondence for specific safety instructions.

Cair LGL 1mm Lateral Extension Set Recall

ANSM has mandated a recall of specific lots of Cair LGL 1mm lateral extension sets (Prolongateur Cair LGL 1mm latéral) at the agency's request. The manufacturer Cair LGL has implemented the lot withdrawal, and affected users have received notification letters dated 02/04/2026. The recall is registered under ANSM reference number R2607673.

Getinge Steam Sterilizer Safety Recall for Pre-September 2019 Devices

ANSM has recorded a safety action (R2609375) initiated by Getinge Sterilization AB regarding steam sterilizers manufactured before September 4, 2019. Healthcare facilities using affected devices have received a manufacturer letter with safety instructions. This recall targets hospital pharmacies, health establishments, and city care structures in France.

Cook Medical Product Recall - Multiple Medical Device References

ANSM issued a safety recall notice (Ref. R2607073) for multiple Cook Medical medical devices distributed in France. Affected products include Blue Rhino G2 tracheostomy kits (the only products distributed in France), central venous catheters, pleural drainage devices, NCompass biliary stone extractors, and CTO-12 micro wire guides. Users who received the affected products should have received direct notification from Cook Medical.

Minoxidil Hair Growth Spray Recalled - Non-Child-Resistant Packaging

CPSC has ordered DrHealBeauty to recall approximately 6,200 Tuymec Minoxidil Hair Growth Kits due to packaging that fails to meet child-resistant requirements under the Poison Prevention Packaging Act. The recall involves products sold on Amazon.com from June through August 2025 for about $24. No injuries have been reported. Consumers should contact DrHealBeauty for a free replacement bottle with child-resistant closure.

Granitestone Sauté Pan Recall - 740K Units Due to Burn Hazard

CPSC announced recall of approximately 740,000 Granitestone Diamond Pro Blue stainless steel sauté pans due to metal caps on handle screws that can detach and forcefully eject when heated, posing impact and burn hazards. At least 98 incidents reported, including one consumer with bruising and burn injuries. Remedy is full refund. Consumers should stop using and return pans to importer E Mishan & Sons, Inc.

TecFlox Hair and Beard Growth Serum Recall - Non-Child-Resistant Packaging

CPSC has recalled approximately 900 TecFlox Hair and Beard Growth Serum bottles due to violation of the Poison Prevention Packaging Act. The bottles contain minoxidil but lack required child-resistant packaging, posing a risk of serious injury or death to children if ingested. Consumers should immediately secure bottles out of reach of children and contact TecFlox for free replacement bottles.

ELENKER Bed Rails Recalled Due to Entrapment and Asphyxiation Hazard

CPSC announced a recall of approximately 30 ELENKER Portable Bed Rails sold on Amazon.com between August 2023 and February 2026 for $80. The bed rails violate the mandatory federal standard for adult portable bed rails due to entrapment hazards that can cause serious injury or death by asphyxiation. The recall number is 26-374.

Ocun Condor HMS Triple Carabiners Recalled Due to Fall Hazard

CPSC announced recall of Ocun Condor HMS Triple Locking Carabiners due to gate malfunction where the gate fails to close automatically, posing a risk of serious injury or death from falling. Approximately 295 units sold in the US from February 2025 through February 2026 at prices between $23 and $60. Consumers should stop using the product immediately and contact OCUN NA for a free replacement.

Coluans Christmas Light-Up Rings Recalled Due to Button Battery Ingestion Hazard

The CPSC announced a recall of approximately 3,540 Coluans Christmas Light-Up Rings Party Favors sold on Amazon from August through December 2025 for $15-$20. The light-up rings violate the mandatory toy safety standard because button cell batteries in the LED ring compartment can be easily accessed by children, posing risk of serious injury or death from ingestion. The remedy is a full refund for consumers who dispose of the product.

HTRC and Haisito T400 Battery Chargers Recall - Fire Hazard

CPSC has issued a mandatory recall (26-379) for approximately 4,800 HTRC and Haisito T400 battery chargers manufactured by Huizhou Haitan Technology Co., Ltd. of China due to fire hazard. The chargers can ignite or cause connected batteries to ignite, posing risk of serious injury and death. The firm reports 33 incidents including fires and explosions, 3 burn/smoke inhalation injuries, and $224,000 in property damage.

Sam's Club Children's Pajama Recall - Burn Hazard

CPSC and Sam's Club announce recall of approximately 18,000 Member's Mark Children's Valentine SS Notch Collar Pajama Sets due to violation of mandatory federal flammability standards for children's sleepwear, posing a burn hazard. Consumers who purchased the recalled pajamas (sold at Samsclub.com December 2025 through January 2026 for about $14) should immediately stop use and contact Sam's Club for a full refund. Recall number: 26-380.

Samson International Recalls Bellevue and Oaklynn Canopy Bed Frames Due to Impact and Injury Hazards

The CPSC announced a mandatory recall of Samson International's Universal Broadmoor brand Bellevue and Oaklynn canopy bed frames (about 5,600 units in the US; 516 in Canada) due to canopy beam collapse hazard during bed movement. Five collapse incidents were reported with four injuries (shoulder and head contusions). Consumers must contact the firm for a free repair kit.

Gavoyeat Halloween Light-Up Rings Recalled - Button Battery Hazard

CPSC announced a mandatory recall of approximately 800 Gavoyeat Halloween Light-Up Rings Party Favors due to accessible button cell batteries that pose a risk of serious injury, internal chemical burns, or death to children if ingested. The product violates the mandatory federal safety standard for toys. Seller CSZWEICD (Shenzhen Weichaoda Technology Co., Ltd.) is offering refunds. Units were sold on Amazon.com from June 2025 through January 2026 for approximately $15.

Beestech Spiral Tower Toys Recalled Due to Choking Hazard

CPSC issued a mandatory recall of Beestech spiral tower toys (model Bee-210316-01) due to violation of the federal small ball ban under 16 CFR 1500.18, posing a deadly choking hazard to children under three years. Approximately 200 units sold on Amazon from November through December 2025 for $15 are affected. Consumers must stop use immediately and contact Beestech for a full refund.

Sangohe Bed Rails Recall Expanded - Entrapment Hazard

CPSC has reannounced and expanded an existing recall of Sangohe adult portable bed rails (models 504E and 504Q) due to entrapment and asphyxiation hazards. The recall now covers approximately 36,500 units, up from 26,200 units in the January 2026 recall. The products violate the mandatory standard for adult portable bed rails and do not bear required warning labels. Consumers should immediately stop use and contact Sangohe for a full refund.

Modified GlcNAc-1-Phosphotransferase sequences, patent application

USPTO published patent application US20260092263A1 for modified, truncated GlcNAc-1-Phosphotransferase (PTase) amino acid sequences that retain phosphotransferase activity. The application, filed August 4, 2025 (Application No. 19289364), covers truncated PTase forms lacking or with modified linkers and/or lacking the C-terminal transmembrane and cytosolic domain, demonstrating retained ability to phosphorylate lysosomal or non-lysosomal target proteins.

Glucosyltransferase Mutant Converting Rebaudioside D to Rebaudioside M

USPTO published patent application US20260092262A1 for Shandong Benyue Biological Technology Co., Ltd covering a glucosyltransferase mutant enzyme that catalyzes conversion of Rebaudioside D (RD) to Rebaudioside M (RM). The mutant contains specific amino acid substitutions at positions 84, 88, 126, 196, and 379 and exhibits significantly higher enzyme activity than wild-type variants. The application was filed September 26, 2025.

Bacteriophage structural proteins via cell-free expression system

The USPTO published patent application US20260092261A1 for multi-peptide structures comprising heterologous functional sites derived from bacteriophage structural proteins produced via cell-free expression. The application, filed by Elisabeth Falgenhauer and co-inventors Friedrich Simmel, Kilian Vogele, and Sophie von Schönberg, covers compositions and methods for universal anti-microbial applications in medicine, chemistry, biotechnology, agriculture, and food industry.

Double Tagged Serratia Marcescens Nuclease Patent Application

USPTO published patent application US20260092265A1 for a double-tagged Serratia Marcescens Nuclease (SMN) engineered with a C-terminal Chitin Binding Domain (CBD-tag) and a 6-mer poly-histidine tag connected by a Gly-Ser linker. Inventors: Dapeng Sun, Aine Quimby, Zhenyu Zhu. Application No. 19324955 was filed September 10, 2025.

Low-Temperature Preservation Cabinet with Temperature Isolation for Biological Samples

USPTO published patent application US20260092260A1 by Genepoint Technologies (Shanghai) Co., Ltd. for a low-temperature preservation cabinet designed for biological samples, featuring a storage region, equipment region, and temperature isolation zone between them. The filing date was December 8, 2025, with application number 19412761.

Fusion protein complexes for epigenetic regulation, cancer treatment

USPTO published patent application US20260092267A1 by inventors Seung Ja Oh and Na Ly Tran for fusion protein complexes including transcription enhancers and dCas9 proteins for epigenetic regulation. The application covers complexes with guide RNAs (gRNAs) for inducing apoptosis of colorectal cancer cells and compensating for rhodopsin deficiency to treat ocular diseases.

Cell Adhesion System for Interspecies Chimeras

USPTO published patent application US20260092259A1 by inventors Jun Wu, Emily B. Ballard, and Jia Huang for a cell adhesion system enabling formation of interspecies chimeras through engineered cells expressing antigen-binding proteins or antigens with cell membrane signaling peptides. The invention facilitates generation of organs, organoids, or tissue masses from human and non-human chimeric animals for potential transplant applications.

CRISPR Enzymes and Systems

The USPTO published patent application US20260092266A1 by Feng Zhang et al. for engineered CRISPR-Cas systems comprising multimeric complexes with β-CASP polypeptides and small Type II-B, II-C, and II-D Cas proteins for modifying target polynucleotides. The application (No. 19388533) was filed November 13, 2025, and published April 2, 2026.

SMARCA2/4 Degrader Compounds and Compositions Patent

USPTO published patent application US20260092071A1 for compounds of Formula II as SMARCA2 or SMARCA4 degraders, including their pharmaceutical compositions and uses. The application (No. 19112750) was filed on September 22, 2023, with 14 inventors including Shaomeng Wang and colleagues. This is a publication of a patent application in the field of heterocyclic compounds for potential therapeutic use.

Aldose Reductase Inhibitors for Skin Aging and Cardiovascular Disorders

USPTO published patent application US20260092072A1 by inventor Andrew WASMUTH for aldose reductase inhibitor compounds. The application covers novel pharmaceutical compositions for treating skin aging, cardiovascular disorders, renal disorders, cancer, diabetes complications, and related conditions. The filing (Application No. 19414626) was submitted December 10, 2025, and classified under CPC codes C07D 495/04 and C07H 15/26.

Substituted Indazoles IRAK4 Inhibitor Patent Application

The USPTO published patent application US20260092069A1 by inventors Terstiege, Schiesser, Xue, Chang, and Berggren for substituted indazoles as IRAK4 inhibitors with potential therapeutic utility. The application (No. 19343252) was filed September 29, 2025 and published April 2, 2026. IRAK4 inhibitors target inflammatory and autoimmune pathways.

Novel Heterocyclic Compounds Patent Application

The USPTO published patent application US20260092073A1 by Hoffmann-La Roche Inc. for novel heterocyclic compounds with general formula I, including compositions and methods of use. The application (Filing Date: 2025-10-15) covers compounds where R1, R2, R9, A1, Rx and Ry define specific substituents. Inventors include David BON, Lea Aurelie BOUCHE, Wolfgang GUBA, and others. CPC Classification: C07D 498/04.

Annelated Pyridines as Steroidogenesis Inhibitors

USPTO published patent application US20260092074A1 by Hoffmann-La Roche covering annelated pyridine compounds as steroid synthetase inhibitors for pharmaceutical use. The application, filed September 25, 2023, discloses small-molecule heterocyclic compounds (C07D class) with applications in steroid hormone regulation. Inventors include Qingzhong Hu, Lina Yin, and Haiyan Li.

Heterocyclic JAK Inhibitors and Canine Atopic Dermatitis Treatment

The USPTO published patent application US20260092070A1 filed by Andrew Antony Calabrese and David T. Stanton for heterocyclic compounds that inhibit Janus Kinase 1 (JAK-1) enzymes. The compounds are designed for treating inflammatory disorders in non-human mammals, specifically canine atopic dermatitis. The application was filed December 2, 2025, under Application No. 19405620.

Treatments for Inflammation - Connexin Hemichannel Modulators

USPTO published patent application US20260091017A1 by inventors Shome, Mugisho, and Rupenthal for inflammation treatment compounds and methods using connexin hemichannel modulators, inflammasome modulators, and pannexin channel modulators. The application covers compositions for treating ocular and dermatological diseases characterized by inflammasome-mediated inflammation through systemic and topical administration. Application No. 19342361 filed September 26, 2025.

Patent for micheliolide compositions to increase muscle mass

USPTO published patent application US20260091019A1 by Korea Institute of Science and Technology for a pharmaceutical composition containing micheliolide as an active ingredient for increasing muscle mass, improving muscle function, or preventing or treating muscular disease. The application (No. 19302634) was filed August 18, 2025 and published April 2, 2026, listing 12 inventors including Myungsuk Kim and Choong-Gu Lee.

Chrysin Pinocembrin CAPE Composition for Neuroinflammation Prevention

The USPTO published patent application US20260091016A1 claiming a composition comprising chrysin, pinocembrin, and CAPE (caffeic acid phenethyl ester) for preventing or treating neuroinflammation and associated neuropsychiatric and neurological diseases. Application No. 18904297 was filed October 2, 2024. The composition is classified under CPC codes A61K 31/352, A61K 31/216, A61K 35/644, and A61P 25/28.

Treatment of Acute Cannabinoid Overdose

USPTO published patent application US20260091020A1 for methods of treating acute cannabinoid intoxication and metrics for evaluating cannabis intoxication. Inventors are Joseph Fenton LAWLER, Daniel Pawel SCHNEEBERGER, and Kenneth C. CUNDY, with application filing date of September 25, 2023.

Panobinostat Combination Therapy for Cholangiocarcinoma Treatment

The USPTO published patent application US20260091021A1 covering combination therapies comprising panobinostat for treating cholangiocarcinoma. The application (No. 19413668, filed December 9, 2025) names seven inventors and claims pharmaceutical compositions combining panobinostat with cytotoxic agents.

Neurotoxin Compositions for Treating Gastroparesis

USPTO published patent application US20260091094A1 disclosing neurotoxin compositions and methods for treating gastroparesis. Inventors Gregory F. Brooks and Eric Carter filed the application on December 9, 2025, under application number 19413766. The publication constitutes prior art as of April 2, 2026.

Netrin-1 peptide amphiphiles treat central nervous system injury

USPTO published patent application US20260092252A1 for Netrin-1 mimetic peptide amphiphiles for treating central nervous system injury. The application covers peptide compositions and methods of use. Inventors include Samuel Isaac Stupp, Cara Stephanie Smith, and Zaida Alvarez Pinto.

Heparan-N-sulfatase purification via multi-mode chromatography

The USPTO published patent application US20260092264A1 on April 2, 2026, disclosing a novel method for purifying heparan-N-sulfatase using multi-mode chromatography combined with caprylate precipitation. Invented by six researchers, the method removes host cell proteins and improves purity and stability of the enzyme for potential pharmaceutical applications.

ActRIIB ectodomain variants treating metabolic disorders and fibrosis

USPTO published patent application US20260092096A1 for Activin receptor type IIB (ActRIIB) ectodomain variants fused to Fc domain for treating metabolic disorders, diabetes, obesity, fibrosis, and muscle atrophy. The application (No. 19206991) was filed May 13, 2025, by inventors Maureen D. O'Connor-McCourt et al.

Adeno-Associated Virus Producer Cell Lines Patent Application

The USPTO published patent application US20260092284A1 for Adeno-Associated Virus (AAV) producer cell lines and methods of producing AAVs. The application, filed August 15, 2025, covers nucleic acids encoding helper genes and AAV genes under inducible promoter control, as well as mammalian cell lines for AAV production. Inventors include Bingnan Gu, Gang Li, and Caitlin Tripp.

JUCED Trademark - Beverages and Supplements (Class 005)

USPTO published trademark application TM79440005 for "JUCED" covering fruit beverages, vitamin drinks, and dietary supplements under Class 005. The mark was filed on 2025-11-27 and published for opposition on April 1, 2026. No compliance obligations or deadlines result from this publication.

VOCO MTA VPT trademark published for dental materials

The USPTO published VOCO MTA VPT (Application No. 79440442) for opposition, a trademark for pharmaceutical products and materials for the dental field including dental restoration materials, filling materials, cements, base materials, and capping materials. The application was filed on 2025-11-28 and published on 2026-04-01.

FOLLY Hair Growth Gummy Trademark Published

The USPTO published trademark application TM79441174 for FOLLY, covering dietary and nutritional supplements in gummy form for promoting hair growth and general health and well-being. The trademark was filed on November 27, 2025, and published on April 1, 2026, initiating a 30-day opposition period during which third parties may challenge the registration.

BEAUTY WITHOUT COMPOMPISE Trademark Application - Class 005

The USPTO published trademark application TM79441342 for 'BEAUTY WITHOUT COMPROMISE' in Class 005 (Pharmaceuticals), covering pharmaceutical preparations, sanitary preparations, dietetic substances, and vitamins across 847 units. The application was filed November 28, 2025, and published for opposition on April 1, 2026.

Beautiful Nutrition US trademark application published April 1st

Beautiful Nutrition US trademark application published April 1st

Amorus Pharmaceutical Trademark Application

The USPTO published trademark application TM79441630 for AMORUS covering pharmaceutical goods and medical apparatus including filled syringes, dermatological products, injectable dermal fillers, and related medical instruments. The mark was filed on November 27, 2025 and published on April 1, 2026, opening a standard 30-day opposition period for third parties.

Alcotra Trademark Application - Published for Opposition

USPTO published trademark application TM79419459 for ALCOTRA for opposition, covering goods and services in Classes 1, 3, 4, 5, 33, and 35 including pharmaceuticals, chemicals, alcoholic beverages, fuels, and retail services. The application was filed on 2024-09-24 and published on 2026-04-01.

LBA Laboratoires De Botanique Trademark Application

USPTO published trademark application TM79424086 for LBA LABORATOIRES DE BOTANIQUE AVANCÉE BAULIEU in International Class 005 covering cosmetics, beauty products, spa services, and retail store operations. The application was published for opposition on April 1, 2026, initiating a 30-day opposition period during which third parties may challenge the registration.

Probiotic Preparations Trademark Application - Class 5

The USPTO published trademark application TM79441709 for probiotic preparations covering goods in International Class 5 (pharmaceuticals) and Class 3 (cosmetics). The application, filed on November 27, 2025, includes probiotic supplements, medicated preparations, dietary supplements, and bacterial formulations for medical and veterinary use. Publication initiates a 30-day opposition period during which third parties may challenge the registration.

Broad Spectrum Antiviral Compositions and Methods

The USPTO published patent application US20260092059A1 by Evrys Bio, LLC covering novel thiazole- and isoquinoline-containing compounds for treating broad-spectrum viral infections. The compounds demonstrated inhibition of HCMV, influenza viruses, Zika virus, BK Virus, and RSV in cell-based assays. The application (No. 19342999) was filed September 29, 2025, and published April 2, 2026.

Isotopically enriched psychedelic analogs for brain disorders

The USPTO published patent application US20260092060A1 for isotopically enriched analogs of 2-bromo-LSD, LSD, ALD-52, and 1P-LSD developed by inventors Matthew Duncton and Samuel Clark. The compounds are directed toward treating neurologic and brain disorders. The application was filed on June 5, 2025, under Application No. 19228993.

Break the Boundaries Trademark - Pharmaceuticals Class 005

USPTO published trademark application TM79442531 for "Break the Boundaries" covering pharmaceutical information services, medical research including gene therapy and stem cell services, clinical trials, SaaS/cloud platforms, and medical equipment rentals under Class 005. The application was published April 1, 2026, initiating the standard opposition period.

MOLECULE 46 Trademark Registration

The USPTO published trademark application TM79442804 for MOLECULE 46 in Class 5, covering medical genetics services, in vitro diagnostic preparations, and medical testing instruments. The publication initiates the opposition period during which third parties may challenge registration.

MMAFIT Trademark Application Published for Opposition

USPTO published trademark application TM79443328 for MMAFIT on April 1, 2026. The application covers goods and services including dietary supplements, food substances for medical use, clothing, footwear, and fitness-related entertainment services. The publication initiates a 30-day opposition period during which third parties may file objections.

Ricola Trademark Application Published for Opposition

The USPTO published Ricola's trademark application (TM79443437) for opposition on April 1, 2026. The application covers goods in International Class 005, including pharmaceutical products, vitamin supplements, medicinal herbal teas, food supplements, and confectionery. Third parties have a 30-day window to file opposition proceedings.

JET BLUE BITE Trademark for Impression Materials

USPTO published the JET BLUE BITE trademark (Serial No. 79443987) for impression materials for dental use. The trademark application was filed on November 28, 2025, and published on April 1, 2026. Third parties have a 30-day opposition period following publication.

WET&FORGET Trademark Application Published for Opposition

The USPTO published trademark application TM79444339 for WET&FORGET covering fungicides, pest control preparations, cleaning products, and related maintenance services in International Classes 1, 3, 5, and 37. The trademark application entered the opposition period on April 1, 2026, allowing third parties with standing to challenge registration.

HYDROBEEF Protein Trademark Application

The USPTO published trademark application TM79445678 for "HYDROBEEF" covering hydrolyzed animal protein raw materials, protein supplements, protein bars, and protein-enriched beverages. The application was filed on November 27, 2025, and published for opposition on April 1, 2026. Interested parties have a 30-day window to file opposition if they believe registration would cause confusion with existing marks.

Water bottles, tableware, jewelry trademark published Apr 01

Water bottles, tableware, jewelry trademark published Apr 01

LUNA trademark published for opposition, medical products

The USPTO published trademark application TM79443850 for LUNA on April 1, 2026. The mark covers sanitary products for medical use including dressing material and teeth filling material. The opposition period is now open for interested parties to challenge the registration.

Methods and Systems for Ablation of the Renal Pelvis

Verve Medical, Inc. filed a patent application (US20260091000A1) with the USPTO on April 2, 2026 for methods and systems of renal pelvis ablation to treat renal nerves. The application covers apparatus and systems for delivering heat or extracting heat through the renal pelvis wall, or delivering active substances to ablate tissue lining. Inventors include Terrence J. Buelna, Adam Gold, and Rahul Rao.

Heterocyclic Compounds for Treatment of Disease

USPTO published patent application US20260092064A1 for heterocyclic compounds and compositions for treating disease, filed by inventors Raju Mohan, John Nuss, and Jason Harris on May 14, 2025. The application was published April 2, 2026, covering compounds classified under CPC codes including C07D 471/04, A61K 31/41, and A61P therapeutic categories.

Seven inventors file PROTAC protein degradation compounds patent

Seven inventors file PROTAC protein degradation compounds patent

Pyridine Carboxamide Compounds for Treating Medical Conditions

The USPTO published patent application US20260092062A1 for pyridine carboxamide compounds and their use in treating medical conditions. The application was filed by inventors Todd Bosanac, Nathan Oliver Fuller, Robert Owen Hughes, Guy Bemis, and Janeta Valentina Popovici Muller on September 26, 2023, and published on April 2, 2026.

Fused Bicyclic RAF Inhibitors and Methods for Use Thereof

The USPTO published patent application US20260092063A1 for fused bicyclic RAF inhibitors as potential cancer therapeutics, including colorectal cancer treatment. Inventors include Andrew Belfield, Clifford David Jones, Jean-François Margathe, and Chiara Colletto. The application was filed on 2025-05-12 under Application No. 19205876.

Novel synthetic routes for macrocyclic heterocycle manufacturing

USPTO published patent application US20260092066A1 on April 2, 2026, disclosing novel synthetic methods for preparing macrocyclic heterocycle intermediates. The application (filed June 18, 2025, Application No. 19242506) covers efficient methods for synthesizing key intermediates in the preparation of Compound (I) with broad substituent applicability.

Crystalline Solid Forms of BET Inhibitor for Cancer Treatment

The USPTO published patent application US20260092065A1 for crystalline solid forms of BET protein inhibitors (BRD2, BRD3, BRD4, BRD-t) useful in cancer treatment. Seven inventors (Chen, Jia, Liu, Qiao, Wu, Zhou, Li) filed the application on September 23, 2025. The application claims novel solid forms, preparation methods, and intermediates for the therapeutic compound.

Method for Preparing Amidines from N-(alkyl lactams) via Dehydration Catalysis

USPTO published patent application US20260092067A1 disclosing a method for preparing amidines from N-(amino-alkyl) lactams via dehydration using heterogeneous catalysts including cerium oxide, boron phosphates, zirconium compounds, and phosphotungstic acid. The application (No. 19108987) was filed September 4, 2023 and published April 2, 2026, listing inventors Nicola Vecchini and Federico Mondini. This represents a new synthetic route for amidine compounds used in pharmaceutical and fine chemical synthesis.

PRC2 Inhibitor Patent for Cancer Treatment, Forms

USPTO published patent application US20260092068A1 for physical forms of PRC2 inhibitor compounds for cancer treatment. Inventors: Mohammad AL-SAYAH and Robert Ronald MILBURN. Application filed September 13, 2023, classified under C07D 487/04 (heterocyclic compounds - organic chemistry). The patent covers the physical forms, pharmaceutical compositions, and methods of treating cancer by administering the compound.

Phase-Changing Matrix for 3D Organoid Culture with Mesenchymal Stem Cells

The USPTO published Application US20260092254A1 claiming a composition for three-dimensional cell and organoid culture comprising a phase-changing matrix with partially ordered polypeptide encapsulating bone-marrow derived or adipose-derived mesenchymal stem cells. The application was filed on September 21, 2023 (Application No. 19113814). This publication provides public notice of the claimed invention for examination purposes.

Pepmixes for Multiviral CTL Generation

USPTO published patent application US20260092256A1 by Baylor College of Medicine covering methods of generating CTLs (cytotoxic T lymphocytes) targeting antigens from multiple viruses. The invention uses peptide mixtures exposed to PBMCs with IL4 and IL7 expansion. Published April 2, 2026, Application No. 19020866.

Methods for Generating Hematopoietic Progenitor Cells

The USPTO published patent application US20260092257A1 covering methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells using chemically-defined culture media. The application was filed October 2, 2025, under Application No. 19347888. Inventors include Angelica Gomes Ueltschy and Michael Elias.

Methods of Recellularizing Tissue Transplant for Improved Transplantability

The USPTO published patent application US20260092253A1 for methods of recellularizing an organ or tissue matrix for improved transplantability. Inventors are Doris A. Taylor and Stefan M. Kren. The application was filed December 9, 2025, under application number 19413394. This publication provides public notice of the pending patent application but does not grant any patent rights.

Cell Based Assays for Botulinum Neurotoxins Serotype-Specific

USPTO published patent application US20260092255A1 for serotype-specific cell-based assays used in characterizing Clostridia botulinum neurotoxins. The assays utilize genetically modified cells capable of discriminating between different serotypes of clostridium neurotoxins without requiring serotype-specific neutralizing antibodies or competing heavy chains. Inventors: Ward Tucker, Francis Mark Dunning, Tim Piazza. Application No. 18920316.

ALT-803 IL-15 Soluble Fusion Molecules and Methods

The USPTO published patent application US20260092097A1 for ALT-803, a complex of interleukin-15 (IL-15) superagonist mutant and dimeric IL-15 receptor α/Fc fusion protein. The application covers compositions and methods for enhancing immune response against neoplasia (multiple myeloma, melanoma, lymphoma) or viral infections (HIV). Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han. Application filed June 25, 2025.

Recombinant Vaccine Against Helminths in Pichia pastoris

USPTO published patent application US20260092089A1 by Fundação Oswaldo Cruz disclosing recombinant production of Sm14 Schistosoma mansoni vaccine antigen using genetically engineered Pichia pastoris strains with methanol-inducible (AOX1) and constitutive (GAP) promoters. The application covers synthetic gene construction, fermentation processes, and protein purification methods scalable for industrial vaccine manufacturing.

Novel CXC receptor ligands from GCP2

USPTO published patent application US20260092091A1 for novel polypeptide ligands of CXCR1 and/or CXCR2 derived from GCP2. The application (No. 19120219) was filed October 11, 2023, by inventors Kouvatsos, Day, Dell'Accio, and Caxaria. The invention covers polynucleotides encoding the ligands, compositions, and uses thereof.

Interleukin-2 for Treating Autism Spectrum Disorder

USPTO published patent application US20260092095A1 by INSERM covering interleukin-2 (IL-2) for treating autism spectrum disorder (ASD). The application also extends to preventing ASD in at-risk children or through maternal administration during pregnancy. Assignee is INSERM (Institut National de la Santé et de la Recherche Médicale, France).

Princeton University patent for cloacaenodin, antimicrobial lasso peptide

Princeton University patent for cloacaenodin, antimicrobial lasso peptide

Engineered cytokines, AI-designed polypeptides, pharmaceutical compositions

The USPTO published patent application US20260092094A1 disclosing engineered cytokines, AI-designed polypeptide structures with modulated stability, potency and developability, and pharmaceutical compositions for therapeutic use. The application, filed May 3, 2024 under Application No. 19481848, covers in silico methods using artificial neural network machine learning protocols and molecular dynamics simulations for engineering cytokines.

Method of Making a Pharmaceutical Composition Comprising a p80 Protein

USPTO published patent application US20260092087A1 by Prime Bio, Inc. covering a method for producing recombinant p80 polypeptide using E. coli culture with L-Arabinose induction. The p80 protein functions as a tight junction modulator to enhance intestinal permeability for therapeutic agents. The application (No. 19352451) was filed October 7, 2025.

Variant Anti-Viral Polypeptides

The USPTO published patent application US20260092088A1 for variant lectin anti-viral polypeptides filed by inventors Cristina BONGIORNI, Mai DU, David A. ESTELL, Keith FROGUE, Amy Deming LIU, and Darshana KADEKAR. The application covers engineered anti-viral lectin compositions for treating and preventing viral diseases in animals, with a filing date of September 19, 2023.

IL-18 Variant Polypeptides for Therapeutic Use

USPTO published patent application US20260092093A1 on April 2, 2026, disclosing engineered IL-18 variant polypeptides with mutations at positions G3, E6, D54, N91, C38, C68, C76, D98, S117, and C127. The variants demonstrate enhanced IL-18Rα binding and reduced IL-18BP binding compared to wild-type human IL-18 (SEQ ID NO: 1). Inventors include Min QIANG, Xi CHEN, Zhengyi WANG, Hui ZENG, Xin ZHENG, Fei ZHANG, Puwei YUAN, and Fan LIU, with original filing dated September 6, 2023.

TNF-alpha Variant Fusion Molecules

USPTO published patent application US20260092092A1 for TNF-alpha variant fusion molecules and their therapeutic uses. Inventors include Robin Allene Aglietti, Susannah Dale Barbee, Peter Michael Bowers, and Melanie Angelika Kleinschek. Application No. 19294212 was filed on 2025-08-07.

NGF Mutein Production Process Patent Application

Chiesi Farmaceutici SpA filed USPTO patent application US20260092090A1 on April 2, 2026, for a process producing nerve growth factor (NGF) and muteins at high purity from recombinant sources. The muteins may exhibit improved detectability and reduced nociceptive activity compared to wildtype human NGF. Application No. 19265384 was filed July 10, 2025.

Methods for Improving Cognitive Function Using ILC2 Cranium Implants

The USPTO published patent application US20260091063A1 by Albany Medical College covering methods to improve cognitive function by implanting activated group-2 innate lymphoid cells (ILC2) into a subject's cranium. The application also discloses methods using cytokines including IL-33, IL-5, IL-7, IL-25, and thymic stromal lymphopoietin to treat aging-associated cognitive decline. Assignee: Albany Medical College; Inventors: Qi Yang; Application No. 19335390.

Oncolytic Herpes Virus Cancer Therapy Vectors

USPTO published patent application US20260091069A1 for an oncolytic herpes simplex virus vector with dual transcriptional and translational control for cancer therapy. The vector incorporates modified ICP27 and ICP34.5 genes under CEA promoter and miRNA-124/143 control respectively, and includes a virus-expressed cytokine cassette encoding IL-12 and IL-15/IL-15RA. Inventors include William Wei-Guo Jia, Dmitry V. Chouljenko, and six others.

TSLP Treatment Using Oligonucleotide siRNA and ASO Compositions

The USPTO published patent application US20260091053A1 disclosing oligonucleotide compositions (siRNA and antisense oligonucleotides) targeting Thymic Stromal Lymphopoietin (TSLP) for treatment of TSLP-related diseases. The application covers methods of treating airway disorders by administering oligonucleotides specific to the long isoform of TSLP. Inventors include Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, and David Rozema. The application was filed on May 19, 2025.

MicroRNA from Rhodiola for Fibroplasia Treatment

USPTO published patent application US20260091052A1 filed by Beijing Baishihekang Pharmaceutical Technology covering microRNA derived from Rhodiola root for prevention and treatment of fibroplasia medical signs and syndromes. The application (No. 19319016) was filed September 4, 2025 and published April 2, 2026, listing five inventors including Chengyu Jiang and Jianchao Du. CPC classifications indicate pharmaceutical compositions and nucleic acid technologies.

BCL-XL/BCL-2 Degraders and Uses Thereof

The USPTO published patent application US20260092057A1 for BCL-XL/BCL-2 degrader compounds and methods of using the same for treating conditions such as cancer. The application was filed on May 12, 2023, by inventors including Huijun Dong, Bin Yang, and others, and covers novel chemical compositions under CPC classifications including C07D 417/12, C07D 471/04, and related therapeutic uses.

Aromatic Acetylene Derivative, Preparation Method Therefor, And Pharmaceutical Use Thereof

USPTO published patent application US20260092055A1 by Zhejiang Hisun Pharmaceutical Co., Ltd. for aromatic acetylene derivatives useful as LpxC inhibitors for treating bacterial infections. The application covers the chemical compounds, preparation methods, and pharmaceutical compositions. Application No. 19112826 was filed September 28, 2023.

Fused Ring STAT6 Inhibitor for Atopic Dermatitis Treatment

The USPTO published patent application US20260092054A1 disclosing a fused ring compound with STAT6 inhibitory activity for treating atopic dermatitis and allergic diseases. Invented by Yoshitake Sumikawa, Issei Akahoshi, and Masaya Kato, the application (No. 19116232) was filed September 29, 2023 and published April 2, 2026. The claimed compound and pharmaceutical compositions target inflammatory conditions via STAT6 pathway inhibition.

KHK Inhibitor Heterocyclic Compounds Patent Application

The USPTO published patent application US20260092053A1 for KHK (ketohexokinase) inhibitor heterocyclic compounds, filed August 22, 2025. The application includes nine inventors and covers compounds of a specified formula with variable substituents defined in the specification. The compounds are classified under multiple CPC categories including C07D 409/14, C07D 401/14, and related pharmaceutical compound classifications.

Pyrimidine Compounds for Cancer Prevention Treatment

The USPTO published patent application US20260092051A1 for pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers. Inventors include In Hwan Bae, Ji Sook Kim, Jae Yul Choi, and others. The application (No. 19203828) was filed on May 9, 2025, and published on April 2, 2026. This is an informational publication with no compliance requirements.

Muscarinic M1 Receptor Compound Treats Alzheimer Disease

USPTO published patent application US20260092052A1 for a nitrogen-containing heterocyclic compound functioning as a muscarinic M1 receptor positive allosteric modulator. The compound is intended for prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, and dementia with Lewy bodies. Inventors include Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, and Makoto Kamata. Application No. 19010914 was filed on January 6, 2025.

Methods of Making Trans Isomeric Forms of G Protein-Coupled Receptor Modulators

The USPTO published patent application US20260092049A1 disclosing methods for synthesizing trans isomeric forms of G protein-coupled receptor (GPCR) modulators with high trans isomeric purity. The application names eight inventors and covers pharmaceutical compositions and synthetic routes for producing these receptor modulators. This publication establishes priority rights for the claimed invention under 35 U.S.C.

Small Molecule Degraders and Fluorescent Probes of PXR

USPTO published patent application US20260092058A1 disclosing compounds, compositions, and methods for degrading pregnane X receptor (PXR) protein. The invention relates to decreasing adverse drug reactions associated with administration of anticancer agents, antibacterial agents, non-steroidal anti-inflammatory agents, or anticonvulsant agents. Application No. 18902844 was filed September 30, 2024.

Melanocortin-4 Receptor Agonists for Obesity and Diabetes Treatment

The USPTO published patent application US20260092056A1 for melanocortin-4 receptor agonists developed by eight inventors. The compounds of Formula 1 demonstrate agonist activity against melanocortin-4 receptors and may be useful in preventing or treating obesity, diabetes, inflammation, and erectile dysfunction.

Chemokine receptor modulators and C07D heterocyclic compounds patent application

USPTO published patent application US20260092050A1 for chemokine receptor modulators and C07D heterocyclic compounds. The application discloses novel compounds for modulating chemokine receptor activity with potential therapeutic uses. Inventors include Parcharee Tivitmahaisoon, David J. Wustrow, Mikhail Zibinsky, and Omar Robles. Filing date was January 17, 2025.

Fat tissue drug delivery system for cancer treatment

USPTO published patent application US20260090990A1 for a fat tissue-based drug delivery system designed for cancer treatment. The invention comprises fat tissue or derivatives thereof for delivering molecules, preferably antitumor drugs. The application (No. 19307845) was filed August 22, 2025, with inventors including Augusto Pessina, Giulio Alessandri, Carlo Tremolada, and Offer Zeira.

Pouch Dispensing System for Topical Anesthetic

USPTO published patent application US20260090987A1 for a pouch dispensing system for topical anesthetic. Invented by Andrew Albee, the application (No. 19347190, filed 2025-10-01) covers an apparatus including a pouch, cover material, and topical anesthetic for oral application.

Pharmaceutical Compositions Comprising Maralixibat and Uses Thereof

The USPTO published patent application US20260090993A1 by Mirum Pharmaceuticals, Inc. for pharmaceutical compositions comprising maralixibat as an active ingredient. The application covers the use of these compositions as solid dosage drug products for treating cholestatic pruritus and cholestatic liver disease. The application was filed on April 9, 2025, and contains 8 CPC classifications related to drug formulations.

Tablet Formulation Patent for HIV Capsid Inhibitor and NRTTI

The USPTO published patent application US20260090994A1 for tablet formulations combining an HIV capsid inhibitor with a nucleoside reverse transcriptase translocation inhibitor (NRTTI) for treating HIV infections. The application was filed on August 29, 2025 under Application No. 19314157. Inventors include Benjamin Chal, Jay Poorna Reddy, Dhananjay Devidas Marathe, and eight others.

Hydroxypropyl methylcellulose powder compositions and applications

USPTO published patent application US20260090992A1 for homogenized hydroxypropyl methylcellulose powder compositions containing chemical signaling agents and optionally biologically active agents, with particle diameters of 20-500μm. Inventors: Todor A. Popov and Peter David Josling. Application No. 19409272 was filed December 4, 2025.

Oligopeptide Inhibits Angiogenesis and Vascular Function

The USPTO published patent application US20260091078A1 covering an oligopeptide composition of 3-7 amino acids that inhibits angiogenesis and vascular function. The oligopeptide comprises defined sequence patterns with basic, small, polar, and hydrophobic amino acid residues. The application claims priority from July 7, 2020.

Antimicrobial peptide Halymorin variants and methods of using the same

USPTO published patent application US20260092082A1 by Antinbio, Inc. disclosing antimicrobial peptide Halymorin variants comprising amino acid sequences SEQ ID NOs: 2-12. The peptides demonstrate antimicrobial activity against Gram-negative bacteria including Campylobacter jejuni, Escherichia coli, Salmonella Typhimurium, and Klebsiella pneumoniae. Applications cover pharmaceutical compositions, food additives, cosmetics, and hygiene products, as well as methods for treating bacterial infectious diseases.

Anti-GCC Antibodies and CARs for Immunotherapy

USPTO published patent application US20260091061A1 disclosing anti-GCC single domain antibodies and chimeric antigen receptors (CARs) for cancer immunotherapy. The application, filed September 28, 2023, names Xiaohu Fan, Panglian Xu, Qiuchuan Zhuang, Min Wei, Jiangjing Tang, Chenchen Zheng, and Xu Fang as inventors. This publication does not create any immediate regulatory obligations.

Antigen Receptors and Uses Thereof

USPTO published patent application US20260091060A1 by Holger Voss et al. covering recombinant antigen receptors and engineered T cells for disease treatment. The application (No. 18905085) was filed October 2, 2024 and published April 2, 2026. The invention relates to treating diseases by targeting cells expressing specific antigens using engineered T cell therapy.

Vancomycin Derivatives with Siderophore Modification as Novel Antibiotics for Gram-Negative Bacteria

Research Triangle Institute filed USPTO patent application US20260092083A1 on April 2, 2026, disclosing novel vancomycin derivatives with siderophore modification designed as antimicrobials against Gram-negative bacteria including Acinetobacter baumannii and Escherichia coli. The application, filed March 6, 2024 under Application No. 19162234, covers compounds for treating antimicrobial-resistant infections.

Dual Target Binding Peptide Composition for Active Targeting DDS

USPTO published patent application US20260092084A1 by MESCUE-JANUSYS INC. for a dual target-binding peptide composition with hydrophilic and hydrophobic regions for active targeting drug delivery systems. The application (No. 18876803) was filed June 23, 2023 and published April 2, 2026.

Cyclic Prosaposins Peptides and Uses Thereof - Cancer Treatment

USPTO published patent application US20260091083A1 filed by Children's Medical Center Corporation for cyclic prosaposin peptides used in cancer treatment and inflammatory diseases. The application (No. 19186486) was filed on April 22, 2025, and published April 2, 2026, naming Randolph S. Watnick as inventor.

Synthetic Triplex Peptide Nucleic Acid-Based Inhibitors for Cancer Therapy

The USPTO published patent application US20260092085A1 by inventors Bahal, Dhuri, and Slack disclosing novel peptide nucleic acid (PNA) oligomers designed to target microRNA-155 (miR-155) for cancer therapy. The application demonstrates in vivo efficacy in xenograft mouse models showing reduced tumor growth. The PNA oligomers form PNA/RNA/PNA triplex structures when binding target RNA sequences.

Fc-IL2 variant cancer therapy combination patents

USPTO published patent application US20260091062A1 by Hoffmann-La Roche Inc. covering recombinant Fc domain-IL-2 variant polypeptides combined with membrane-anchored antigen binding polypeptides for cancer treatment. The application (No. 19272092) was filed July 17, 2025, and published April 2, 2026.

Saposin-A Derived Peptides with Anti-Angiogenic Activity for Tumor Treatment

The USPTO published patent application US20260091079A1 by Children's Medical Center Corporation covering Saposin-A derived polypeptides with anti-angiogenic activity. The peptides consist of 9 or fewer amino acid residues containing the active core sequence DWLP. The disclosed invention can be used to inhibit tumor growth and cancer metastasis.

BacPROTACs for Targeted Protein Degradation in Bacteria

Washington University published patent application US20260091118A1 for bivalent agents (BacPROTACs) designed for targeted protein degradation in mycobacteria and other bacteria, including methods for reducing antibiotic resistance. The application (No. 19312129, filed August 27, 2025) covers compositions and methods for treating antibiotic-resistant bacterial infections.

Coronavirus Vaccine Nucleic Acid LNP Patent

USPTO published CureVac SE's patent application (US20260091107A1) for nucleic acid sequences and compositions suitable for coronavirus vaccines, particularly COVID-19, delivered via lipid nanoparticle (LNP) technology. The application covers compositions, vaccines, first and second medical uses, and methods of treatment or prevention. Filed as Application No. 19317057 with priority date September 2, 2025.

Macrophage targeting drug conjugates with mannose linker

The USPTO published patent application US20260091117A1 for macrophage targeting drug conjugates developed by P.I.F. Entrepreneurs Ltd. The conjugates comprise a drug moiety, mannose moiety, and linker (hydrazone or oxime group) for targeted therapeutic delivery. Application No. 19411275 was filed December 7, 2025.

Targeted Delivery System Using CD45+ Leukocyte Cells for Glioma Treatment

USPTO published patent application US20260091119A1 disclosing an isolated targeted delivery system using CD45+ leukocyte cells containing iron binding proteins complexed with therapeutic or diagnostic agents for glioma treatment. Inventors include Magdalena KRÓL and seven co-inventors. The application was filed on September 1, 2023.

Anti-B7-H3 ADC Combined with ATR/ATM Inhibitor for Cancer Treatment

The USPTO published patent application US20260091123A1 by Daiichi Sankyo Company Limited covering a pharmaceutical composition and method of treatment combining an anti-B7-H3 antibody-drug conjugate with an ATR inhibitor or ATM inhibitor for cancer therapy. The application claims the drug-linker conjugate structure and treatment methods. Filing date was October 9, 2025.

Multifunctional drug delivery system for cancer treatment antibodies

USPTO published patent application US20260091125A1 for a multifunctional drug delivery system using inorganic core particles conjugated to antibodies for cancer treatment. The system delivers distinct immunoglobulins to cancerous cells and tissues outside the brain via four-linker architecture. Application filed January 12, 2023; granted Application No. 18865714.

Janus antimicrobial nanoparticles embedded in polymers

USPTO published patent application US20260091127A1 for Janus antimicrobial nanoparticles with distinct hydrophobic and polycationic surfaces embedded in crosslinked polymers. The invention aims to enhance traditional antibiotics and reduce necessary dosages against multi-drug resistant bacteria. Application No. 19344327 was filed September 29, 2025, and published April 2, 2026.

Sevabertinib (Hyrnuo) approved for advanced HER2-positive lung cancer

MHRA granted marketing authorisation to Bayer PLC for sevabertinib (Hyrnuo), a protein kinase inhibitor for adults with advanced HER2-mutated non-small cell lung cancer that has spread or is unresectable. The drug was approved via Project Orbis, a global regulatory partnership. Clinical trials showed a 71% positive response rate in previously treated patients.

Environmental Risk Assessments for Medicines

MHRA published guidance on environmental risk assessments (ERAs) for medicinal products in the UK. The guidance clarifies that all marketing authorisations require evaluation of potential environmental risks under Schedule 8 of the Human Medicines Regulations. Marketing authorisation holders must assess physicochemical and ecotoxicological properties and environmental fate of active substances, proposing mitigation measures where risks cannot be excluded.

Cosmetic Base Patent with Polymer Formula for Moisturizing Effect

Shiseido Company, Ltd. filed USPTO Patent Application US20260090976A1 for a cosmetic base composition containing a polymer formula designed to provide both use sensation and moisturizing effect. The polymer has a number-average molecular weight not exceeding 10,000 and an IOB value between 0.4 and 1.8. The application was published on April 2, 2026 with Filing Date August 31, 2023.

Mascara Composition with Sunflower Seed Wax

L'ORÉAL published patent application US20260090978A1 for mascara composition containing sunflower seed wax, tribehenin, and behenyl behenate. The invention provides improved aesthetics with total wax content of 5-35% by weight and combined wax blend of 5-20%. Application filed September 2024 with inventors David CHAN and Geoffrey WHITE.

Contact Lenses with Medicament Coating for Drug Release in Glaucoma Treatment

MEDIPRINT OPHTHALMICS INC. filed patent application US20260090984A1 for contact lenses incorporating medicament coatings for controlled drug release, specifically targeting glaucoma treatment through sustained delivery of drugs such as bimatoprost. The application covers the lens composition including N-vinylpyrrolidone, soaking solutions, and methods for loading and refreshing drug-eluting contact lenses. This patent application (No. 19411056, filed December 5, 2025) names six inventors including Praful Doshi and Brandon Huang.

Pediatric parenteral nutrition, oil-in-water emulsion, multi-chamber containers

USPTO published patent application US20260090983A1 for pediatric parenteral nutrition formulations comprising lipid emulsions in oil-in-water form. The application also covers multi-chamber containers for separating carbohydrate, amino acid, and lipid formulations until administration. Inventors include Jean-Luc Trouilly, Mary Hise Brown, Laurent Jeannin, Julien Hecq, and Julie Fahier.

Transdermal Delivery Formulations

USPTO published patent application US20260090981A1 for LifeActive, Inc., covering transdermal delivery formulations combining weak organic acids with fatty acid microemulsions for epicutaneous administration of therapeutic agents, drugs, and nutrients. The formulations are designed for use in high humidity conditions such as showers or saunas.

Cosmetic Compositions for Skin Firming Using Escin Extracts

USPTO published Mary Kay Inc.'s patent application for cosmetic compositions containing escin and botanical extracts for treating sagging, loose skin and improving facial contouring. The application includes methods comprising topical application of compositions with escin, Ascophyllum nodosum extract, caffeine, Coleus barbatus extract, and other plant-based ingredients. This is an informational publication with no regulatory compliance requirements.

Cosmetic Uses of Phaeodactylum Tricornutum Hydrolysate

USPTO published patent application US20260090979A1 by MICROPHYT covering cosmetic uses of a hydrolysate derived from an ethanolic extraction coproduct of the microalgae Phaeodactylum tricornutum. The invention targets skin exfoliation and reduction of skin microrelief for cosmetic and nutraceutical applications.

Water-in-oil cosmetic composition

USPTO published patent application US20260090977A1 for a water-in-oil cosmetic composition comprising specific silicone components (A) and (B) along with silicone powder (C), designed to improve stability, spreadability, and layered makeup durability. The application was filed September 7, 2023, with inventors Masaru Miyauchi, Masayuki Konishi, Yoshinori Inokuchi, and Ryuji Horiguchi.

Compositions and Methods for Enhancing Wnt Signaling for Treating Cancer

USPTO published patent application US20260091038A1 on April 2, 2026, disclosing compositions and methods for enhancing Wnt signaling pathway activities for treating cancer, particularly cancers with APC gene mutations. The application covers pharmaceutical compositions containing GSK-3 inhibitors, preferably LY2090314, encapsulated in nanoparticles. Inventors are George Eng, Omer Yilmaz, and Jonathan Braverman. Application number 19294146 was filed August 7, 2025.

Biomarkers for Alzheimer's Disease Diagnosis and Treatment

USPTO published patent application US20260091025A1 by Electrophoretics Limited covering biomarker panels for Alzheimer's disease diagnosis and treatment. The application claims panels including PP1 regulatory subunit 14A, CNPase, and phosphorylated tau proteins, along with methods for diagnosing and staging neurocognitive disorders using casein kinase 1 delta inhibitors.

Mycobacterium Vaccine Compositions for Immune System Modulation

The USPTO published patent application US20260091098A1 by inventor Bruce S. Gillis covering methods and compositions using killed or inactivated Mycobacterium or antigenic fragments for modulating immune system function. The application was filed September 12, 2025, under Application No. 19327636. This is a published patent application and does not grant any rights or impose obligations on third parties at this time.

Methods Of Treating Plantar Fibromatosis

The USPTO published patent application US20260091093A1 disclosing methods of treating plantar fibromatosis. The application (No. 19288249) was filed August 1, 2025, and names five inventors including James P. Tursi and Jeffrey David Lehrman. The invention relates to therapeutic methods using compositions classified under A61K 38/4886.

BabA Antibodies for Preventing H. pylori Gastric Disease

USPTO published patent application US20260091099A1 by inventors Borén and Hammarström covering recombinant blood group antigen-binding adhesin (BabA) compositions that raise antibodies targeting conserved epitopes in the Leb antigen binding domain of BabA. The application discloses methods for preventing H. pylori-associated gastric diseases including gastric cancer, peptic ulcers, and gastritis without eradicating the infection.

Tick Immunity Compositions and Methods

USPTO published patent application US20260091095A1 by inventors Erol Fikrig and Sukanya Narasimhan for compositions and methods generating tick immunity. The application (No. 19320550) was filed September 5, 2025, and published April 2, 2026. The invention covers pharmaceutical compositions for tick immunity under CPC classifications A61K 39/0003, A61P 33/14, and related subclasses.

Edwards EVOQUE Tricuspid Delivery System Labelling Recall

Health Canada issued a Type II voluntary recall for Edwards EVOQUE Tricuspid Delivery System (Model 9850TDS) affecting all lots. This labeling correction does not require product return but is intended to update device labeling to support proper use and optimal performance. Healthcare providers using this device should review updated labeling materials.

Dimension Creatinine CRE2 Medical Device Recall

Health Canada issued a Class Type II medical device recall for Siemens Healthineers Dimension® Creatinine (CRE2) diagnostic reagents due to potential imprecision in quality control and patient sample results. Affected lots GA6307 and BA7005 (catalog 10872079) may produce inaccurate creatinine measurements on the Dimension system. Healthcare facilities using these products should immediately quarantine affected inventory and contact Siemens for return or replacement options.

CFTR Modulator Patent, Pharmaceutical Compositions, Treatment Methods

The USPTO published patent application US20260092047A1 disclosing CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator compounds of Formula (I), their pharmaceutical compositions, methods of treating cystic fibrosis, and processes for making the modulators. The application also covers solid state forms of Compound 1 and salts and solvates thereof. The application was filed on May 13, 2025, with Application No. 19206359.

Quinoline cGAS Antagonist Solid Forms and Salts

The USPTO published patent application US20260092048A1 for solid forms and salts of a quinoline cGAS antagonist compound, filed by inventors Jian Qiu, Qi Wei, Heping Shi, Lijun Sun, and Zhijian Chen (Application No. 19316546, filed September 2, 2025). The application discloses the compound's cGAS antagonist properties, methods of preparation, pharmaceutical compositions, and use in medical therapy.

Quinoline Butenamide Maleate Salts for EGFR Cancer Treatment

The USPTO published patent application US20260092046A1 covering maleate salt forms of a quinoline-based butenamide compound designed to target epidermal growth factor receptor (EGFR) family kinases for cancer treatment. Invented by Quinhong Lu and colleagues, the application discloses crystalline forms, preparation methods, and pharmaceutical compositions. The patent application was filed on May 5, 2025, and published on April 2, 2026.

Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors

The USPTO published patent application US20260092045A1 for substituted benzofuran, benzopyrrole, benzothiophene compounds and structurally related compounds as complement system inhibitors. The application was filed on December 8, 2025, with 11 named inventors including Pravin L. Kotian, Yarlagadda S. Babu, and Weihe Zhang. The compounds may be formulated as pharmaceuticals for treating diseases characterized by aberrant complement system activity.

Pyrimidine Derivative for Inflammation Treatment

USPTO published patent application US20260092044A1 by ASKA Pharmaceutical Co., Ltd. for a pyrimidine derivative with mPGES-1 inhibitory activity for treating inflammation, pain, and rheumatism. The application was filed December 8, 2025, and names Makoto Okada, Youichi Nakano, Takashi Nose, Satoshi Maeda, and Tomoaki Watanabe as inventors.

Novel Benzoxazole Derivative Comprising 4-Amino-Butanamide and Anti-Inflammatory Use

USPTO published patent application US20260092043A1 by EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION disclosing novel benzoxazole derivatives comprising 4-amino-butanamide and their anti-inflammatory pharmaceutical applications. The application (No. 19115423) was filed March 14, 2023 and published April 2, 2026.

Ipconazole preparation process patent

USPTO published patent application US20260092042A1 by inventors Mittal, Kini, Mukadam, and Shelkar disclosing a process for preparing Ipconazole, a triazole fungicide used in agriculture. The application, filed September 13, 2023, and published April 2, 2026, claims a cost-effective and environmentally friendly synthesis method suitable for large-scale industrial production.

Process for Preparing Fluoro-imino-dihydropyrimidine Compounds

The USPTO published patent application US20260092041A1 for Adama Makhteshim Ltd., covering a process for preparing fluoro-imino-dihydropyrimidine compounds and derivatives. The application was filed on 2025-10-08 under Application No. 19352947. Inventors include Gal Suez, Samaa Alasibi, and Yaakov Mines.

Cyclopropane Carboxylic Acid Synthesis Methods

The USPTO published patent application US20260092040A1 for methods of preparing substituted cyclopropane carboxylic acid compounds. Inventors Nikolaos Papaioannou, Michael Jonathan Fray, Andreas Rennhack, and Sarah Jocelyn Fink filed the application on September 20, 2023 (Application No. 19113778). The application covers synthetic routes for these chemical compounds, which have potential uses in pharmaceutical development.

Dual Inhibitors for Alzheimer's Disease Treatment

USPTO published patent application US20260092039A1 for dual inhibitors (soluble epoxide hydrolase and glutaminyl cyclase inhibitors) useful for Alzheimer's disease treatment. Inventors from Spain and Germany filed Application No. 19161626 on March 4, 2024, with the application published April 2, 2026. The compounds also reduce pro-inflammatory cytokines, exhibit low cytotoxicity, and have good blood-brain barrier permeability.

FOXG1 Gene Therapy Patent - Viral Vectors

USPTO published patent application US20260091140A1 for gene therapy constructs and viral vectors treating FOXG1 haploinsufficiency syndrome. Invented by Sarah Elizabeth Sinnett, the application (No. 19346144) includes FOXG1 encoding nucleic acids with miRNA regulatory elements to limit overexpression in vivo.

Broad Institute Gene Editing Patent for SMA Treatment

The USPTO published patent application US20260091141A1 by Broad Institute, Inc. covering gene editing methods, systems, and compositions for treating spinal muscular atrophy (SMA). The application (No. 19288071) was filed on August 1, 2025, and made publicly available on April 2, 2026. Inventors include David R. Liu, Mandana Arbab, and Zaneta Matuszek. The application covers modified messenger RNAs and delivery methods for treating microbial infections or improving subject health.

AAV Gene Therapy for Hypertrophic Cardiomyopathy

USPTO published patent application US20260091139A1 for AAV gene therapy compositions targeting reduced cardiac myosin binding protein C levels in subjects with hypertrophic cardiomyopathy. The application (filed September 22, 2023, Application No. 19113698) names six inventors including Peter Cameron Colosi and Eduard Ayuso. This is a publication notice with no immediate compliance obligations.

Recombinant AAV Vectors for Treating Proteinopathies in CNS

The USPTO published patent application US20260091134A1 by Shanghai Vitalgen Biopharma Co., Ltd. covering recombinant adeno-associated viral (rAAV) vectors encoding Progranulin (PGRN) and/or Stathmin-2 (STMN2) for treating proteinopathies in the central nervous system. The application, filed November 26, 2025 (Application No. 19401460), includes codon-optimized coding sequences and viral particle compositions.

Rod-Derived Cone Viability Factor Fusion Protein

USPTO published patent application US20260091133A1 disclosing a fusion protein comprising rod-derived cone viability factor-S (RdCVF-S), a hydrophilic peptide, and a signal peptide. The invention covers encoding nucleic acids, viral vectors, and pharmaceutical compositions for potential treatment of ocular conditions. Inventors: Tianci LUO, Daniel LIPUT, Fong Qi LIANG. Application No. 19339969 filed September 25, 2025.

ENHO gene therapy using Adropin for heart failure

The University of Pittsburgh filed a patent application (US20260091136A1) covering gene therapy methods using Adropin encoded by the ENHO gene for preventing and treating cardiometabolic diseases, specifically heart failure with preserved ejection fraction (HFpEF). The application was published on April 2, 2026.

Retron Gene Editing Patent for Human Cell Genome

USPTO published patent application US20260091137A1 for Retron directed gene editing technology applicable to human cell genome editing. The application, filed September 15, 2023, by inventors Brian Busser and colleagues, covers compounds, polypeptides, compositions, and nucleic acid molecules for genome editing. Key CPC classifications include gene editing enzymes and genetic constructs.

Epilepsy Treatment via Thalamus Bistable Opsin Gene Therapy

USPTO published patent application US20260091135A1 for Modulight Bio Ltd. covering methods of treating epilepsy using thalamus-administered bistable type II opsin gene therapy with light activation. The application (No. 19403102) was filed November 27, 2025, and published April 2, 2026. The invention targets drug-resistant epilepsy via optogenetic modulation of thalamic neural circuits.

Variants of Coagulation Factor VIII and Uses Thereof

USPTO published patent application US20260091138A1 by Seattle Children's Hospital covering FVIII (coagulation factor VIII) protein variants with an N2118Q mutation for hemophilia A treatment. The application claims variants with reduced immunogenicity, higher gene expression, increased stability, and enhanced functional activity suitable for protein replacement therapy and gene therapy applications.

Click-to-Release Biotech Patent for Proteins and Peptides

The USPTO published patent application US20260091124A1 by inventor Michael Lukesch for a click-to-release technology involving modified peptides or proteins combined with bioorthogonally modified drugs. The application, filed September 20, 2023, and published April 2, 2026, covers bioorthogonal functional groups that enable targeted drug delivery systems for therapeutic applications.

Hybrid Antibody-Peptide Molecule for Autoimmune Dermatitis

Université Toulouse III – Paul Sabatier has published patent application US20260091122A1 for a hybrid molecule combining an antibody Fc fragment with a peptide targeting autoreactive lymphocytes involved in autoimmune dermatitis. The invention covers the covalent bonding of the Fc portion to the targeting peptide and its therapeutic applications for treating autoimmune skin conditions.

Chimeric Antigen Receptors Binding Nectin-4 for Cancer Treatment

The USPTO published patent application US20260091114A1 by Fred Hutchinson Cancer Center disclosing Chimeric Antigen Receptors (CARs) with binding domains that target Nectin-4, derived from murine antibody M22-321b41.1. The CARs are designed for expression in immune cells to treat Nectin-4-expressing cancers including bladder, breast, ovarian, esophageal, lung, colorectal, and pancreatic cancers. Application No. 19112145 was filed September 14, 2023.

Nanocomposite for Targeted Degradation of Pathogenic Proteins

USPTO published patent application US20260091129A1 by inventors Zhang et al. disclosing a nanocomposite system for targeted degradation of pathogenic proteins using a maleimide-PEG-PLA nanocarrier with cationic lipids and protein-targeting binding peptides. The invention enables degradation of protein aggregates through autophagy pathways, addressing limitations of PROTAC and LYTAC technologies, with applications in anti-tumor treatments and Huntington's disease.

AAV NDP Gene Therapy for NDP-Related Diseases Including Norrie Disease and Retinopathy

USPTO published patent application US20260091131A1 by University of Massachusetts inventors disclosing AAV constructs encoding wildtype or codon-optimized NDP gene sequences for treating Norrie disease, diabetic maculopathy, retinopathy, and other NDP-related retinal diseases. The application, filed October 10, 2023, covers methods of administration including intravitreal injection for retinal neovascularization and exudation conditions.

PSMA-STEAP1 Dual Variable Domain Immunoglobulin DVD-Ig Molecules and Drug Conjugates

AbbVie Inc. filed US Patent Application US20260091121A2 for dual variable domain immunoglobulin (DVD-Ig) molecules binding human PSMA and STEAP1 antigens and their drug conjugates. The application (No. 18958236) was published on April 2, 2026 following filing on November 25, 2024. Competitors should monitor this IP position as it may cover cancer therapeutic constructs targeting these prostate cancer-associated antigens.

Incretin analog tri-receptor agonist compositions for weekly dosing

USPTO published patent application US20260091087A1 disclosing dosing regimens and compositions for long-acting incretin analog tri-receptor agonists targeting GIP, GLP-1, and glucagon receptors for once-weekly administration. The application (No. 19393199) was filed November 18, 2025, and names Tamer Coskun, Zvonko Milicevic, and Shweta Urva as inventors.

4-Hexylresorcinol pharmaceutical composition for bone disease treatment

The USPTO published patent application US20260091001A1 filed by Kyungpook National University Industry-Academic Cooperation Foundation for a pharmaceutical composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for the prevention or treatment of bone diseases, including osteoporosis. The application claims formulations including ointments that demonstrated improved bone thickness, density, and strength in osteoporosis-induced animal models by promoting osteoblast differentiation and suppressing osteoclast proliferation.

Methods Of Treating Plantar Fibromatosis

The USPTO published patent application US20260091092A1 on April 2, 2026, disclosing methods of treating plantar fibromatosis. The application (No. 19288073) was filed August 1, 2025, with inventors James P. Tursi, Luis A. Ortega, Qinfang Xiang, Saji Vijayan, Jeffrey David Lehrman, and David Hernandez. The patent covers therapeutic approaches using compounds classified under A61K 38/4886 and A61K 9/0019.

Halogenated Phenol Antimicrobial Composition

The USPTO published patent application US20260091002A1 filed by Industry Academic Cooperation Foundation of Yeungnam University for a halogenated phenol derivative composition with antimicrobial and antibiofilm activity against Staphylococcus aureus and pathogenic microorganisms. The application, filed June 10, 2025, covers the composition, methods of use, and treatment of biofilm-related infections.

P55gamma as Therapeutic Target for Aortic Dissection

The USPTO published patent application US20260091091A1 claiming p55γ as a therapeutic target for aortic dissection (AD). The inventors from China demonstrated that p55γ overexpression inhibits AD formation and elastic fiber degradation in β-aminopropionitrile fumarate (BAPN)-induced mouse models. The patent covers using p55γ as a screening target for drugs to prevent and/or treat AD.

Incretin Analog Dosing and Composition Methods for GLP-1 GIP GCG Tri-Agonists

The USPTO published patent application US20260091088A1 disclosing dosing regimens and compositions for long-acting incretin analogs comprising glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) tri-receptor agonists suitable for once-weekly administration. The application covers methods for treating metabolic conditions including obesity (A61P 3/04) and diabetes (A61P 3/10).

RSV vaccine method, single dose, stronger immunity

The USPTO published patent application US20260091105A1 by inventors Peter L. Collins and Ursula J. Buchholz covering a method of vaccination using a single dose of a recombinant RSV lacking the M2-2 protein. The vaccine reportedly induces a stronger immune response than previous candidates despite being more restricted in replication. The application (No. 18898953) was filed September 27, 2024.

Amino acid-modified lipids enable RNA delivery via lipid nanoparticles

USPTO published patent application US20260091126A1 for amino acid-modified lipids designed for RNA delivery via lipid nanoparticles (LNPs). The application, filed September 19, 2023, by inventors Kun Cheng and Pratikkumar Vinodchandra Patel, covers siRNA, mRNA, miRNA, shRNA, and oligonucleotide delivery formulations. The technology targets oncogene silencing applications.

Cell-Penetrating Peptides for Muscular Dystrophy Treatment

USPTO published patent application US20260091120A1 by Matthew Wood et al. covering cell-penetrating peptides with dual hydrophobic domains for treating genetic disorders, specifically Duchenne muscular dystrophy. The application (filed October 21, 2025) discloses peptide compositions and conjugates with therapeutic molecules. This is a publication of a pending application and does not yet grant enforceable patent rights.

Stabilized Enveloped Viruses by Spray-Drying and Lyophilization

The USPTO published patent application US20260091106A1 on April 2, 2026, disclosing compositions and methods for making thermostable enveloped viruses using spray-drying and lyophilization techniques. The inventions aim to reduce degradation, preserve virus activity and titer, and prolong storage stability for transport and later use. Application 19348562 was filed October 2, 2025 by inventors Coleman, Randolph, Schwartz, and Garcea.

Vaccine Comprising PBMCs Loaded with NKT Cell Ligand and Antigen

USPTO published patent application US20260091112A1 by CELLID CO., LTD. for an immunotherapeutic vaccine composition comprising peripheral blood mononuclear cells loaded with alpha-galactosylceramide (an NKT cell ligand) and tumor antigens. The filing date was September 15, 2023, with publication on April 2, 2026.

CureVac SE Bunyavirales vaccine patent application

CureVac SE Bunyavirales vaccine patent application

Biallelic Knockout of CTLA4

The USPTO published patent application US20260091113A1 by inventor Rafi Emmanuel covering compositions and methods for biallelic knockout of CTLA4 using RNA guide sequences. The application includes 4,891 sequence variants (SEQ ID NOs: 1-4891) with potential therapeutic applications. Filed September 18, 2023; published April 2, 2026.

ASXL1 Disruption in T Cells for Immunotherapy Enhancement

The USPTO published patent application US20260091115A1 filed by St. Jude Children's Research Hospital, Inc., covering modified immune effector cells with disrupted ASXL1 genes for enhanced immunotherapy function. The application includes claims for the modified T cells, methods of generating them, and methods for using them in adoptive cell therapy treatments for diseases.

Nucleic Acid Vaccine Patent Application

USPTO published patent application US20260091104A1 filed by ModernaTX, Inc. for nucleic acid vaccine compositions and methods. The application (No. 19188713) covers ribonucleic acid vaccines encoding antigens, filed on April 24, 2025, and lists three inventors: Giuseppe Ciaramella, Axel Bouchon, and Eric Yi-Chun Huang.

7-Azaindole Analogs and Serotonin Agonists for Neurological Disorders

The USPTO published patent application US20260092034A1 for 7-azaindole analogs as serotonin receptor agonists for treating neurological disorders. Assigned to Kuleon LLC with inventor David Gilles, the application covers both hallucinogenic and non-hallucinogenic compounds. The patent application was filed December 8, 2025, under application number 19412382.

Crystalline Benzamide Salt Forms for T-Type Calcium Channel Diseases

USPTO published patent application US20260092037A1 disclosing crystalline salt forms of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide useful for treating T-type calcium channel diseases including epilepsy, essential tremor, and major depressive disorder. The application (No. 19311876) was filed August 27, 2025, naming inventors David T. Jonaitis and Lisa McCracken.

Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof

The USPTO published patent application US20260092038A1 disclosing novel cannabinoid receptor 1 (CB1) antagonists/inverse agonists for treating metabolic disorders including diabetes, dyslipidemia, cardiovascular disorders, obesity, and cancer. Invented by Marshall Morningstar, the application covers compound compositions and therapeutic uses. Filing date was September 26, 2025.

Hydrochloric acid salt of 5-HT2C agonist patent application

USPTO published patent application US20260091039A1 for a crystalline hydrochloric acid salt of (R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (a 5-HT2C agonist). The application includes pharmaceutical composition claims and methods of use. Inventor: Anthony Clyde Blackburn. Application No. 19344622.

Crystalline T-type calcium channel salt patent

The USPTO published patent application US20260092036A1 by inventors Daniel Thomas Walters and Thomas San Ie on April 2, 2026. The application discloses Pattern D, a crystalline form of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide hydrochloride salt trihydrate (Compound 1), along with pharmaceutical compositions and methods for treating neurological and psychiatric disorders. The application was originally filed on August 27, 2025, with application number 19311030.

Indole Derivatives as Serotonergic Agents for CNS Disorders

USPTO published Application US20260092035A1 disclosing indole derivatives of general Formula (I) as serotonergic agents useful for treating CNS disorders including psychosis and mental illnesses. Inventor Abdelmalik Slassi filed the application on December 9, 2025 (Application No. 19413522). This patent application publication represents a routine intellectual property filing with no compliance obligations or regulatory deadlines for third parties.

Heterocyclic Compound Orexin 2 Receptor Agonist Narcolepsy Treatment

The USPTO published patent application US20260092033A1 for a heterocyclic compound as an orexin 2 receptor agonist for treating narcolepsy. Inventors include researchers from a Japanese pharmaceutical company. The application claims priority to Application No. 19287436 filed July 31, 2025. This is a standard pharmaceutical patent filing that does not impose regulatory obligations on third parties.

Ligand-Enabled Scalable C-H Hydroxylation of Benzoic and Phenylacetic Acids at Room Temperature

The USPTO published patent application US20260092029A1 by Yu/Quan et al. disclosing methods for Pd-catalyzed C-H hydroxylation of benzoic and phenylacetic acids at room temperature using bifunctional pyridone-carboxylic acid ligands and aqueous hydrogen peroxide as oxidant. The application, filed September 7, 2023, also covers synthesis of polyfluorinated natural products and ibuprofen hydroxylation.

Cellular Oxidative and Mitochondrial Stress Protection Compositions

NUCHIDO LIMITED filed USPTO Patent Application US20260090969A1 for compositions protecting cells from oxidative and mitochondrial stress. The application discloses a combination of bioactive compounds including NMN, NR, resveratrol, curcumin, and other cellular stress protectors for pharmaceutical and cosmetic applications. Published April 2, 2026.

Sodium DNA Lipid Nanoparticle Drug Delivery Patent

USPTO published patent application US20260090968A1 for a lipid nanoparticle composition containing sodium DNA as an active ingredient, with applications in pharmaceutical drug delivery systems. The composition includes sodium dilauramidoglutamide lysine as an amphiphilic surfactant, distearoylphosphatidylcholine as an auxiliary surfactant, cholesterol as a stabilizer, and auxiliary stabilizers including PEG-120 stearate, polyglyceryl-4 caprate, and PEG-PCL copolymer. Filing date is October 10, 2023.

Composition for Promoting the Skin Microbiome

USPTO published patent application US20260090967A1 for a skin microbiome promoting composition. The application claims a combination of carbon sources (glucose, fructose, saccharose, maltose, maltodextrin, pyruvic acid, pyruvate, lactic acid and lactate) and nitrogen sources (alanine, glycine, arginine and urea), and/or caprylic/capric triglycerides. Inventors include Jennifer Huepeden, Mirja Laschet, Karen Tom Dieck, Heike Foelster, and Sabine Sellckau.

Cannabinoid Emulsion Compositions for Treating Ophthalmic Conditions

Rhodes Technologies published patent application US20260090988A1 for stable cannabinoid emulsion compositions designed for ocular delivery to treat ophthalmic conditions including glaucoma. The application, filed July 29, 2025, and published April 2, 2026, names inventors Ping Chang, Zhenze Hu, and Yuanyuan Tao. This publication represents a patent application only and does not grant enforceable patent rights.

Polymer Nanoparticle Compositions for NF1 Treatment

The USPTO published patent application US20260090998A1 covering methods of using block copolymer nanoparticles for delivering nucleic acids to treat Neurofibromatosis Type 1 (NF1). The application (filed October 2, 2025) names 12 inventors and discloses compositions and methods for in vivo therapeutic delivery using polymer nanoparticles.

Cat Food Composition for Treating or Preventing Urolithiasis

The USPTO published patent application US20260090570A1 for a cat food composition designed to treat or prevent urolithiasis (urinary stones) in cats. The wet and dry compositions include omega-3 fatty acids from flaxseed and fish oil, along with pH-modifying ingredients such as calcium sulfate, methionine, sodium acid pyrophosphate, taurine, and potassium sulfate. The application was filed on October 1, 2024, under application number 18903721.

Orodispersible Estetrol Dosage Unit Patent

USPTO published patent application US20260090995A1 by ESTETRA SRL covering an orodispersible solid pharmaceutical dosage unit containing estetrol particles (0.1-25 wt.%) for sublingual, buccal, or sublabial administration. The dosage unit weighs 30-1,000 mg, contains at least 100 μg of estetrol component, and is manufactured via wet granulation of particles sized 2-50 μm. Application No. 19340502 was filed September 25, 2025.

LifeActive Transdermal Delivery Formulations Patent Application

USPTO published patent application US20260090982A1 for LifeActive, Inc., covering transdermal delivery formulations for therapeutic agents, drugs, and nutrients. Inventors include Calvin Dexter Morris, Burgess A. Thomasson Jr., and Scott A. Jenkins. The application discloses homogeneous transdermal formulations combining weak organic acid accelerants with fatty acid microemulsions for enhanced skin absorption.

Urolithin oral care compositions patent application

USPTO published patent application US20260090966A1 for urolithin-based oral care compositions including toothpaste, mouthwash, gels, and chewing gum with therapeutic or cosmetic effects. The application covers compositions comprising urolithins, methods of treatment, and formulations with additional active ingredients such as fluoride. Inventors include Christopher L. Rinsch, Davide D'Amico, Anurag Singh, and Charlotte Tissot.

Cat Food Composition for Treating Urolithiasis and Reducing Hairballs

The USPTO published patent application US20260090571A1 for a cat food composition targeting urolithiasis (urinary stones) and hairball reduction. Inventors Nolan Z. Frantz, Angela M. Gajda, and Todd Harper developed wet and dry formulations incorporating omega-3 sources (flaxseed, fish oil), acidifiers (calcium sulfate, SAPP), methionine, taurine, and dietary fiber to achieve urine pH between 6.15-6.85 and reduce RSS struvite to ≤1.8 and RSS oxalate to ≤6.0.

Aspirin Oral Mucosal Formulations

USPTO published patent application US20260090985A1 for oral mucosal aspirin formulations (91-200mg micronized) with buffer and surfactant components. The application, filed by inventor James Dzandu, covers sublingual and buccal delivery formulations with pH ≤3. No regulatory obligations or compliance deadlines are imposed by this patent publication.

Delayed Release IBD Treatment Composition

Aihol Corporation filed patent application US20260090996A1 for a delayed-release oral pharmaceutical composition containing mesalamine and hyaluronan layers for treating inflammatory bowel disease. The USPTO published the application on April 2, 2026, with Application No. 19399068 and a filing date of November 24, 2025. This patent covers novel multi-layer coating technology for targeted drug delivery to the colon.

Micronized Antibodies in Polymeric Particles for Drug Delivery

USPTO published patent application US20260090991A1 for pharmaceutical compositions containing micronized antibodies encapsulated in polymeric particles. The inventors (Mathiowitz, Azagury, Baptista) disclose formulations designed to minimize initial burst release of antibodies. Compositions are formulated for oral, subcutaneous, or percutaneous administration for antibody-based therapies.

Anti-CCR8 antibodies and uses thereof - Vaccinex cancer treatment patents

Vaccinex, Inc. filed patent application US20260091108A1 covering anti-CCR8 antibodies and methods of treating cancer using those antibodies. The application, published April 2, 2026 with filing date November 19, 2025, names 11 inventors including Pamela M. Holland. CPC classifications indicate therapeutic antibody applications in oncology.

Method for Treating Alzheimer's Disease

The USPTO published patent application US20260091109A1 disclosing a method for treating Alzheimer's disease using sequential administration of anti-amyloid beta monoclonal antibodies in increasing doses to reduce ARIA risk. The application, filed June 16, 2025, names James L. Ferrero, Leslie Lugene Williams, and Jeffrey Joseph Sevigny as inventors. This publication provides public notice of a pending patent application but creates no compliance obligations for third parties.

Self-assembling peptide gel for tissue lift, repair

The USPTO published patent application US20260091159A1 by Norchi et al. disclosing compositions containing self-assembling peptides that form stable in situ gels for tissue lift, repair, and bulking applications. The formulations are designed for use during endoscopic, laparoscopic, or open surgical procedures and provide hemostatic properties with adhesion prevention for periods of days to one month.

Metastatic cancer treatment using abscopal effect with radiotherapy

The USPTO published patent application US20260091085A1 assigned to INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a composition comprising type 1 interferon combined with low-dose radiotherapy to induce systemic anticancer effects (abscopal effect) in metastatic cancer sites. The application claims a method where administering type 1 interferon with low-dose radiation to the primary tumor site produces anticancer effects at non-radiated metastatic sites.

Transgenic Non-Human Animals Producing Modified Heavy Chain-Only Antibodies

USPTO published patent application US20260090529A1 disclosing transgenic non-human animals that produce modified heavy chain-only antibodies (HCAbs). The invention involves substituting the native amino acid residue at the first position of framework region FR4 with a different residue to disrupt a surface-exposed hydrophobic patch, potentially improving antibody characteristics. Named inventors include Wim van Schooten, Nathan Trinklein, Shelley Force Aldred, Marianne Bruggemann, and Mike Osborn.

Amylin Receptor Agonist and GLP-1 Receptor Agonist Combination Therapy

USPTO published patent application US20260091086A1 for a combination therapy comprising amylin receptor agonists and GLP-1 receptor agonists. The application, filed on May 19, 2025, covers polypeptide combinations for therapeutic uses including weight management (A61P 3/04). Invented by Sarah WILL, the application represents a potential new approach to metabolic disorder treatment.

Universal T Cell CMV Vaccine for Influenza

USPTO published patent application US20260091102A1 for a universal T cell-based, CMV-vectored vaccine for influenza, filed by Oregon Health & Science University. The invention covers methods of generating immune responses and MHC-restricted T cells for treatment or prevention of pathogenic infections including influenza.

Cancer Treatment Patent - Two-Part Treatment Regime

The USPTO published patent application US20260091097A1 for a two-part cancer treatment regime involving antigen-specific T cell therapy followed by inflammation-inducing treatment. The application, filed on April 18, 2025, covers methods of treating cancer using sequential administration of treatments to generate tumor-specific immune responses. Inventors include Geoffrey Martin Lynn, Christopher Martin O'Brien Garliss, and others.

Lipid Nanoparticle mRNA Vaccines

USPTO published patent application US20260090989A1 by CureVac SE for lipid nanoparticle mRNA vaccine compositions. The application covers cationic lipids according to formulas (I)-(III), PEG lipids per formula (IV), and mRNA encoding antigens for influenza and rabies vaccination. The filing (Application No. 19409837) lists 14 inventors including Patrick Baumhof, Mariola Fotin-Mleczek, and Michael J. Hope.

Lipid Nanoparticles Comprising Nucleic Acids Encoding Therapeutic Genes and Uses in Medical Methods

The USPTO published patent application US20260090997A1 by Sorscher et al. disclosing lipid nanoparticle compositions comprising nucleic acids encoding therapeutic genes for treating cancer. The application was filed September 20, 2023, and published April 2, 2026. Inventors include researchers from Emory University and Georgia Institute of Technology working on targeted gene therapy delivery systems.

Pyocyanin Demethylases Engineered for Bacteria

The USPTO published patent application US20260091089A1 for engineered pyocyanin demethylases with amino acid replacements at positions A53, 173, A87, T91, M99, A129, and K141 of PodA. The application covers compositions, methods, and systems for interfering with bacterial viability through pyocyanin demethylase activity, including synergistic combinations with antibiotics. Application 19312182 was filed August 27, 2025.

Urate Oxidase-Albumin Conjugate Patent Application

USPTO published patent application US20260091090A1 for a urate oxidase-albumin conjugate invented by seven researchers. The conjugate uses three or more albumins conjugated through a linker to a urate oxidase variant, improving half-life and reducing immunogenicity. The invention addresses prevention and treatment of diseases caused by uric acid, such as gout and hyperuricemia.

Cardiac Xenograft Rejection Measurement Methods

The USPTO published patent application US20260091096A1 disclosing methods for measuring cardiac xenograft immune rejection progress. The application covers transgenic pig preparations with reduced glycan antigens (Sda/SDa-like and α-Gal) and recipient immunological response modifications targeting CD46, CD59, CD9, PROCR, and ANXA2. Inventors are Guerard W. Byrne and Christopher G.A. McGregor, with priority date September 15, 2025.

NADC34-like PRRSV-2 Vaccine Plasmid and Mutant Strain rBJ-VVL

Yangzhou University filed a patent application (US20260091100A1) with the USPTO for an rBJ-VVL plasmid and mutant NADC34-like PRRSV-2 strain with tropism for Marc-145 cells. The modified strain incorporates precise mutations at amino acid positions 91/97/98 of GP2a, enabling viral propagation and plaque formation in Marc-145 cells. This represents the first disclosed NADC34-like PRRSV-2-specific vaccine candidate derived from a Marc-145-adapted modified strain.

Culture and Kit-of-Part of Bacterial Strains

USPTO published patent application US20260090557A1 for bacterial cheese culture strains and kits for manufacturing pasta-filata cheese. The application covers galactose-positive Streptococcus thermophilus strains and methods for producing stretched curd cheese using defined culture combinations. Filing date was December 10, 2025.

VMAT2 Inhibitor Heterocyclic Compound and Preparation Method

The USPTO published patent application US20260091029A1 for a class of VMAT2 inhibitor heterocyclic compounds. The application, filed December 9, 2025 under Application No. 19414124, covers compounds represented by formula (I), their stereoisomers, and pharmaceutically acceptable salts. The inventors (Jingwei Tian, Rui Zhang, and seven others) also disclose preparation methods and applications for treating diseases related to VMAT2 and Sigma-1 receptors.

KRAS Inhibitor Heterocyclic Compounds for Cancer Treatment

USPTO published patent application US20260092075A1 for KRAS inhibitor heterocyclic compounds designed for cancer treatment. The application covers novel chemical compounds of specified formula, their pharmaceutical salts, and methods of using these compounds for treating cancer patients. Filing date was September 30, 2025.

Novel Heterocyclic Compounds for Pharmaceutical Use

Hoffmann-La Roche Inc. published patent application US20260092076A1 for novel heterocyclic compounds with pharmaceutical use. The application covers compounds having general formula I with defined R1, R2, R3, A and W substituents, related compositions, and methods of using the compounds. Filing date was October 7, 2025, under Application No. 19351608.

Hydrophobic Cellulose Powder for Cosmetic Applications

USPTO published patent application US20260090962A1 for surface-treated hydrophobic cellulose powder. The invention uses modified dextrin and/or modified amino acids to render cellulose powders hydrophobic, improving dispersibility, feel, and stability. The powders are intended for cosmetic applications including foundations, skin care, and hair care products.

Antiperspirant Cream Patent Application by Lume Deodorant LLC

The USPTO published patent application US20260090961A1 by Lume Deodorant, LLC for an antiperspirant cream composition containing water, an antiperspirant material, alpha-hydroxycarboxylic acid, an oil agent, and a structuring agent, with optional caffeine or xanthine derivatives. The application was filed on September 27, 2024, and names inventors Shannon Klingman, Stephanie Richmond, Rebecca Reynandez, and Nikita Bhatnagar. This is an informational publication of a patent application; no regulatory compliance obligations are created.

Process for Making Aqueous Therapeutic Particles with Nanosized Water Clustering

USPTO published patent application US20260090957A1 for a process and apparatus for manufacturing aqueous therapeutic particles (AQTP) with stable exterior water clustering between 1-300 nanometers. The invention, assigned to a multi-inventor team, claims improved bioavailability for therapeutic compositions including CBD, PNC-27 peptides, pharmaceuticals, and nutraceuticals through a computer-controlled continuous manufacturing process.

Depilatory Emulsion Containing Paclitaxel and Preparation Method

USPTO published patent application US20260090965A1 for a depilatory emulsion containing paclitaxel by inventor Ming Xia. The invention comprises 10-20% oil, 8-12% humectant, 4-6% emulsifiers, 8-12% paclitaxel solution, and auxiliary ingredients, designed to target hair follicles while preventing dermal absorption. A stepwise cooling and gradual emulsification method ensures stable emulsion formation.

Vital Pulp Therapy Using Bioactive Composites

USPTO published patent application US20260090960A1 by Imam Abdulrahman Bin Faisal University for a method of vital pulp therapy using a bioactive capping material. The invention comprises a mixture of glass ionomer cement (GIC) and potassium nitrate (KNO3) in 1-10 wt.% concentration with a solvent. The application was filed September 30, 2024.

Composition Comprising Biosurfactant and Salicylic Acid

USPTO published L'OREAL's patent application for a skincare composition combining glycolipid biosurfactants with salicylic acid derivatives, cationic polymers, and clay for treating acne-prone skin. The application, filed September 30, 2024, covers formulations with water and glycerin solvents for topical use.

Xanthommatin Color Additive for Food Beverage and Drug Compositions

USPTO published patent application US20260090963A1 by inventor Leila Deravi for xanthommatin as an edible color additive for food, beverage, and drug compositions at 0.01-0.5% wt concentration. The application covers substrates including foods, beverages, drinks, medications, and drug forms.

Center for Scientific Review Notice of Closed Meetings

The NIH Center for Scientific Review published a notice announcing five closed meetings scheduled for April 27-28, 2026. The meetings will review and evaluate grant applications for various study sections covering neuroscience, genetics, biochemistry, and health promotion. Meetings are closed under Federal Advisory Committee Act provisions to protect confidential grant information and personal data.

National Eye Institute Meeting Cancellation

The National Eye Institute (NEI) has cancelled a meeting of the Board of Scientific Counselors scheduled for April 6, 2026, from 2:00 to 3:00 p.m. The meeting, which was to be held at NEI headquarters in Bethesda, MD, was previously noticed in the Federal Register on March 26, 2026 (91 FR 14703). A new Federal Register notice will be published once a rescheduled date is determined.

Center for Scientific Review Notice of Closed Meetings

The National Institutes of Health (NIH) Center for Scientific Review published a notice announcing five closed meetings scheduled for April 28-29, 2026. The meetings involve review panels evaluating grant applications in neurological disorders, musculoskeletal sciences, HIV/AIDS research, and neuroimmune/neuroinflammation studies. Meetings will be held virtually and are closed under exemptions for confidential trade secrets and personal privacy protections.

Priority Review Voucher Issuance; KRESLADI Rare Pediatric Disease Product

FDA announced the issuance of a priority review voucher to Rocket Pharmaceuticals, Inc. for KRESLADI (marnetegragene autotemcel), approved March 26, 2026, for treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I). The voucher was awarded under section 529 of the FD&C Act's Rare Pediatric Disease Priority Review Voucher Program. This notice fulfills FDA's statutory requirement to publish voucher awards.

Siren Biotechnology ITM Trademark for Gene Therapy

USPTO published Siren Biotechnology's intent-to-use trademark application for the stylized mark 'SIREN BIOTECHNOLOGY' covering pharmaceutical preparations for gene therapy for cancer treatment and related research and development services. The application (TM99737013) was filed on March 31, 2026, with an Intent-to-Use filing basis indicating the applicant has not yet used the mark in commerce but intends to do so.

THEVO Labs Trademark Application - Dietary Supplements

The USPTO published trademark application TM99737126 for THEVO LABS covering dietary supplements and online retail store services. The application was filed on March 31, 2026, and published on April 1, 2026, initiating a 30-day opposition period during which third parties may challenge the registration.

Advisory Board on Radiation and Worker Health Charter Renewal

The CDC published a notice announcing the charter renewal of the Advisory Board on Radiation and Worker Health (ABRWH) in the Federal Register. The board operates under the Department of Health and Human Services to advise on radiation protection and worker health matters. This renewal continues the board's advisory functions without substantive changes to its mission or authority.

NCVHS Public Meeting Announced for April 2026

The CDC published a Federal Register notice announcing a public meeting of the National Committee on Vital and Health Statistics (NCVHS). The meeting is scheduled for April 16, 2026, from 5:30 p.m. to 7:30 p.m. EDT. Public attendance is permitted; no new regulatory requirements or policy changes are established.

Crysvita Severe Hypercalcemia Risk Communication

Swissmedic, in coordination with Kyowa Kirin, issued a Direct Healthcare Professional Communication (DHPC) warning of severe hypercalcemia risk associated with Crysvita (Burosumab). Cases of elevated serum calcium, including life-threatening hypercalcemia, have been reported, particularly in patients with tertiary hyperparathyroidism. The communication establishes contraindications for patients with moderate to severe hypercalcemia (>3.0 mmol/L) and provides updated monitoring protocols.

Final Dose Trademark - Probiotic Supplements and Vitamins

The USPTO received trademark application TM99208312 for 'FINAL DOSE' filed on May 29, 2025. The application covers International Class 005 products including probiotic supplements, vitamins, dietary supplements, and nutritional products under an intent-to-use basis.

WIZZWELL Incontinence Products Trademark Application

USPTO published trademark application TM99275999 for WIZZWELL, covering incontinence products for men including absorbent pads, disposable bags, and supportive boxer briefs. The application, filed July 10, 2025, claims intent to use the mark by March 31, 2026. No opposition period or compliance deadlines are associated with this application.

GEMSLEAF Trademark Application - Intent to Use

The USPTO received a trademark application for GEMSLEAF filed on July 21, 2025, under Serial No. TM99293830. The application is based on Intent to Use provisions and covers natural herbal supplements, dietary supplements, sleep aid preparations, and various beverages including water, carbonated drinks, and coconut water. The applicant has until March 31, 2026, to either use the mark in commerce or file for extension.

VIGOR&VEDA Ayurvedic herbal wellness trademark application

USPTO received trademark application TM99292393 for VIGOR&VEDA (Intent to Use basis) filed by an undisclosed applicant on July 19, 2025. The application covers online retail services for nutritional supplements and apparel, dietary supplements, and athletic apparel. The statutory use deadline is March 31, 2026.

Lead Traces in Frozen Dinosaur-Shaped Chicken Nuggets Public Health Alert

USDA FSIS issued a public health alert regarding frozen dinosaur-shaped ready-to-eat chicken nuggets found to contain lead traces. The contamination was identified through routine surveillance, prompting concerns about potential health risks to consumers, particularly children. FSIS is working with the firm to remove affected product from the marketplace.

B. Braun Hemodialysis Blood Tubing Set Recall - Air Bubble Risk

Health Canada issued a Type II recall for B. Braun Hemodialysis Blood Tubing Sets (models B3-4630M4705 and B3-3632M3705) due to potential accumulation of small air bubbles in the arterial line caused by adherence of blood gases to tubing under negative pressure. All lots are affected. Healthcare providers should immediately identify and remove affected products from use and contact the manufacturer for return or replacement instructions.

DermaHealer UVB Light Therapy Lamps Recalled for Lacking Canadian Medical Device Licence

Health Canada issued a Type II recall for DermaHealer UVB Light Therapy Lamps (Handheld and Compact models) distributed in Canada without required Canadian Medical Device Licence. The products were sold to customers across Canada by manufacturer DermaHealer USA/UAB FavouritePlus of Tualatin, Oregon. No specific lot or model numbers are available; customers must contact the manufacturer for identification.

Jamieson Laboratories Products Recall - Defective Tamper-Evident Seals

Health Canada issued a Type III recall for Jamieson Laboratories three natural health product capsule lines due to potentially defective tamper-evident seals. Affected products include Joint pain relief capsules (NPN 80140241, lot 70794), Magnesium bisglycinate Capsules (NPN 80131651, 12 lots), and Maca capsules (NPN 80134082, 3 lots). The recall depth extends to wholesalers and retailers. No compliance deadline or penalties are specified.

Kiwi Vacuum Assisted Delivery System Recall - Breakage Hazard

Health Canada issued a Type II recall for Clinical Innovations' Kiwi® Vacuum Assisted Delivery System (model VAC-6000MT) due to a breakage hazard at the Traction Force Indicator joint during use. The device may break when traction is applied at approximately a 45-degree angle, posing a risk during obstetric procedures. Manufacturers will contact affected customers with instructions for product return.

Flamingo Funnel Medical Device Recall - Sterility Loss Risk

Health Canada issued a Type II recall for Flamingo Funnel™ medical devices (lots 8264501, 8264601, 8264701, model SQ-20012-01) manufactured by Nascent Surgical D/B/A SurgiSmoke Solutions. The recall was initiated due to a packaging defect where a non-gamma-compatible drape degraded under heat, causing pinholes and potential loss of sterility. Healthcare providers must immediately stop using affected lots and dispose per national and local regulations.

Health First Vitamin E Recall - Undeclared Active Ingredient

Health Canada issued a Type III recall for Health First Vitamin E capsules (NPN 80089888, lots 14042 and HL2252701) distributed by Health First Network in Hamilton, Ontario. The recall affects retailers and targets products containing an undeclared active ingredient. Consumers are advised to consult healthcare providers before discontinuing use. The recall was initiated on April 1, 2026.